What is HC Wainwright’s Forecast for FibroGen Q2 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of FibroGen in a report released on Tuesday, May 13th. HC Wainwright analyst M. Keller now forecasts that the biopharmaceutical company will earn $0.04 per share for the quarter, down from their previous forecast of $0.05. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.55) EPS and FY2028 earnings at ($0.63) EPS.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.19). The business had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.00 million.

Other equities analysts also recently issued reports about the company. StockNews.com began coverage on FibroGen in a research note on Friday, May 9th. They issued a “hold” rating for the company. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Tuesday, April 1st.

FibroGen Price Performance

NASDAQ:FGEN opened at $0.30 on Thursday. FibroGen has a 1-year low of $0.18 and a 1-year high of $1.53. The firm has a 50-day moving average of $0.32 and a two-hundred day moving average of $0.41. The stock has a market cap of $30.30 million, a P/E ratio of -0.24 and a beta of 0.86.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FGEN. Two Sigma Securities LLC acquired a new stake in shares of FibroGen during the fourth quarter worth approximately $27,000. Velan Capital Investment Management LP acquired a new position in shares of FibroGen during the fourth quarter worth approximately $42,000. XTX Topco Ltd raised its position in FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 77,693 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of FibroGen in the 4th quarter valued at $205,000. Finally, HighTower Advisors LLC lifted its stake in shares of FibroGen by 292.8% during the first quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 301,500 shares during the period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at FibroGen

In related news, CEO Thane Wettig purchased 145,000 shares of FibroGen stock in a transaction on Monday, March 24th. The stock was bought at an average price of $0.35 per share, with a total value of $50,750.00. Following the completion of the transaction, the chief executive officer now directly owns 543,329 shares of the company’s stock, valued at approximately $190,165.15. This represents a 36.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James A. Schoeneck bought 250,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was purchased at an average price of $0.35 per share, for a total transaction of $87,500.00. Following the completion of the purchase, the director now directly owns 323,722 shares in the company, valued at $113,302.70. The trade was a 339.11% increase in their position. The disclosure for this purchase can be found here. 3.07% of the stock is currently owned by company insiders.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.